Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias

Similar documents
Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

Regulatory Challenges across Dementia Subtypes European View

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Agreed by Gastroenterology Drafting Group May Adopted by CHMP for release for consultation 24 May Start of public consultation 8 June 2012

Concept paper on a Guideline for allergen products development in moderate to low-sized study populations

Draft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011

Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension

Issues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital

Agreed by Scientific Advice Working Party January Adoption by CHMP for release for consultation 20 January 2011

1 March 2010 EMA/131300/2010 Human Medicines Development and Evaluation. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom

Initial (Full) Marketing Authorisation application accelerated assessment timetables

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

Discussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013

Submission of comments on 'Policy 0070 on publication and access to clinical-trial data'

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Standard operating procedure

Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018

Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals

Draft Agreed by Cardiovascular Working Party 28 September Adoption by CHMP for release for consultation 12 October 2017

Pharmacovigilance Working Party (PhVWP)

Frequently asked questions

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

European Medicines Agency decision

European Medicines Agency decision

Guidance on format of the risk management plan (RMP) in the EU part II: Module SIV - Populations not studied in clinical trials

Standard operating procedure

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Conclusions of the Paediatric Epilepsy Experts Group Meeting, held in London 1 September 2009

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

The European Medicines Agency (EMA)

Changing diagnostic criteria for AD - Impact on Clinical trials

European Medicines Agency decision

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

European Medicines Agency decision

Inventory of paediatric therapeutic needs

WORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) CHAIRPERSON: Barbara van Zwieten-Boot

Guideline on the demonstration of palatability of veterinary medicinal products

European Medicines Agency decision

EMA confirms recommendations to minimise risk of brain infection PML with Tysabri

Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft

European Medicines Agency decision

Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies

Class waiver list review

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

European Medicines Agency decision

European Medicines Agency decision

Supporting regulatory science outside the EU. The Article 58 procedure. An agency of the European Union

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Qualification opinion, PET Biomarker, Pre-dementia Alzheimer s disease

European Medicines Agency decision

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

European Medicines Agency decision

Overview of the Procedure and interactions between CAT and CHMP

European Medicines Agency decision

European Medicines Agency decision

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Product. Commission. Summary Notification 1. Information issued on. Decision. Issued 2 / affected 3 amended on

European Medicines Agency decision

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

How can the new diagnostic criteria improve patient selection for DM therapy trials

European Medicines Agency decision

Assessment report. for

European Medicines Agency decision

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

European Medicines Agency decision

Draft Agreed by Biosimilar Working Party (BMWP) October Adoption by CHMP for release for consultation 17 November 2011

New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist

Outline. Facts and figures Action plans Early / correct diagnosis Conclusions

European Medicines Agency decision

Inventory of paediatric therapeutic needs

European Medicines Agency decision

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Guideline on influenza vaccines submission and procedural requirements

European Medicines Agency decision

European Medicines Agency decision

Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore

European Medicines Agency decision

PMDA Considerations for Outcome Assessments

Support to paediatric medicines development

Summary. 20 May 2014 EMA/CHMP/SAWP/298348/2014 Procedure No.: EMEA/H/SAB/037/1/Q/2013/SME Product Development Scientific Support Department

European Medicines Agency decision

Community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum

The Committee for Medicinal Products for Human Use

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

European Medicines Agency recommends changes to the use of metoclopramide

Disclosure Statement

PRAC recommendations on signals

Transcription:

15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias Agreed by CNS Working Party February 2012 Adoption by CHMP 15 March 2012 Start of public consultation n/a End of consultation (deadline for comments) n/a Keywords CHMP, EMA, Alzheimer s Disease 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.

1. Introduction Despite the rapid progress in understanding of the neurobiology and pathophysiology of Alzheimer s disease (AD) only cholinesterase-inhibitors and memantine have been approved for the symptomatic treatment with overall limited clinical improvement. Whereas in other diseases (Parkinson s disease) longer lasting symptomatic improvement effects are much more impressive compared to AD, yet no product has been approved for disease modification in any neurodegenerative disorder by regulatory bodies. Unfortunately, many clinical trials recently failed to show symptomatic improvement or promising hints for disease modification in AD, e.g. medicinal products with an Aβ-targeted mode of action. There are now many activities leaving the concept of the full picture of dementia as a first step of diagnosis for AD. This will require new standardisation of diagnostic criteria particularly for earlier disease stages. In consequence new validated assessment tools sensitive to change in the different dimensions of AD are necessary in earlier stages of the disease. If a treatment claim for disease modification is strived for, it has to be shown that the treatment has an impact on the underlying pathophysiology of AD in addition to clinical improvement. This will lead to more complex study designs (adaptive designs, staggered start and withdrawal designs, combination of symptomatic and potential disease modifying compounds, etc.). In addition the progress in qualification and validation of biomarkers might play an important role in future drug development for AD, and regulatory requirements in this process should be specified based on recent scientific advice procedures. 2. Problem statement Two major issues are important for assessment of future clinical trials in AD and other dementias: 1. the change of diagnostic criteria and their validation; 2. the potential use of biomarkers in the different stages of drug development. Recently several papers on new diagnostic criteria for AD have been published. Although full validation of these research criteria has not been finalised they are already being used in ongoing clinical trials. Moreover, several biomarkers including genetic markers, cerebrospinal fluid markers and brain imaging markers (MRI, PET, SPECT) have been studied extensively and are under evaluation. Shortly new evidence from finalised clinical trials and large research consortia like ADNI will be published on the potential use of biomarkers. Consequently, numerous scientific advices have been given for development programs on medicinal products for treatment of AD and recently SAWP published qualification opinions on the use of cerebrospinal fluid markers and hippocampal MRI for enrichment of study populations with patients at risk for or with AD. 3. Discussion (on the problem statement) The following critical aspects should be discussed in a future update of the guideline: The impact of new diagnostic criteria for Alzheimer s disease and other dementias on clinical trial design. The choice of outcome parameters and need for distinct assessment tools with regard to the different disease stages in AD and other dementias (different signs and symptoms, differences in change over time, severity). EMA/CHMP/60715/2012 Page 2/5

Assessment of efficacy and safety in different age groups (e.g. old versus very old). Potential use of biomarkers and their temporal relationship with the phases of AD in different stages of drug development (mechanism of action, use as diagnostic test, enrichment of study populations, stratification for subgroups, safety and efficacy markers, etc.). Design of long-term efficacy and safety studies. Usefulness of combination therapy and corresponding study designs. All pertinent elements outlined in current and future EU and ICH guidelines and regulations should also be taken into account. 4. Recommendation CHMP is well aware of the ongoing clinical trials and validation studies of new diagnostic criteria and potential biomarkers. However, it seems premature to update now the current Guideline on Medicinal Products for the Treatment of Alzheimer s Disease and Other Dementias. As soon as new validated data on diagnostic criteria and potential biomarkers will be available these scientific developments and current experience in SAWP procedures will be taken into consideration for an update of the Guideline on Medicinal Products for the Treatment of Alzheimer s Disease and Other Dementias. Therefore postponement of the update is recommended by CNSWP. 5. Proposed timetable Reconsideration of an update of the CHMP guideline might take place in 2013. 6. Resource requirements for preparation Currently expert consultation is not required. In case of updating the guideline this will be reconsidered depending on the new data and evidence available. The preparation of a future update will involve the CNSWP. Two rapporteurs from the CNSWP will be involved; drafts of the document will be discussed with BSWP, SAWP and other WPs as appropriate. 7. Impact assessment (anticipated) As outlined currently an update of the guideline document is considered premature due to the ongoing basic and clinical research. If these newer data will be available an updated Guideline on Medicinal Products for the Treatment of Alzheimer s Disease and Other Dementias will be helpful to achieve consensus in the evaluation of such products by regulatory authorities in the European Community. Furthermore, it is expected, that such guideline would improve quality and comparability of development programs for this specific indication by pharmaceutical companies. 8. Interested parties The interested parties in the guidance document include learned societies and academia (e.g. European College of Neuropsychopharmacology (ECNP); Alzheimer s Association; European Alzheimer s Disease Consortium (EADC) and others), pharmaceutical industry (e.g. EFPIA and others) and other regulatory agencies. EMA/CHMP/60715/2012 Page 3/5

9. References to literature, guidelines, etc. 1. Albert, M. S., S. T. DeKosky, et al. (2011). "The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & dementia: the journal of the Alzheimer's Association 7(3): 270-279. 2. Ballard, C., S. Gauthier, et al. (2011). "Alzheimer's disease." Lancet 377(9770): 1019-1031. 3. Broich, K., M. Weiergraber, et al. (2011). "Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements." Progress in Neurobiology 95: 498-500. 4. Cummings, J.L. (2011) Alzheimer s disease clinical trials: changing the paradigm. Curr Psychiatry Rep 13: 437-442. 5. Dubois, B., H. H. Feldman, et al. (2010). "Revising the definition of Alzheimer's disease: a new lexicon." Lancet Neurol 9(11): 1118-1127. 6. Dubois, B., H. H. Feldman, et al. (2007). "Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria." Lancet Neurol 6(8): 734-746. 7. Hampel, H., R. Frank, et al. (2010). "Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives." Nat Rev Drug Discov 9(7): 560-574. 8. Hampel, H., G. Wilcock, et al. (2011). Biomarkers for Alzheimer s disease therapeutic trials. Progress in Neurobiology 95: 579-593. 9. Isaac, M., S. Vamvakas, et al. (2011). "Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials." Eur Neuropsychopharmacol 21(11): 781-788. 10. Kester, M.I., P.G. Scheffer, et al. (2011). Serial CSF sampling in Alzheimer s disease: specific versus non-specific markers. Neurobiol Aging Epub ahead of print (July 6). 11. Klunk, W.E. (2011). Amyloid imaging as a biomarker for cerebral ß-amyloidosis and risk prediction for Alzheimer dementia. Neurobiology of Aging 32 (Suppl. 1): S20-S36. 12. Mangialasche, F., A. Solomon, et al. (2010). Alzheimer s disease: clinical trials and drug development. Lancet Neurol 9: 702-716. 13. Manolis, E., S. Vamvakas, et al. (2011). "New pathway for qualification of novel methodologies in the European Medicines Agency." Proteomics Clin Appl 5(5-6): 248-255. 14. McKhann, G. M., D. S. Knopman, et al. (2011). "The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & dementia: the journal of the Alzheimer's Association 7(3): 263-269. 15. Querfurth, H. W. and F. M. LaFerla (2010). "Alzheimer's disease." N Engl J Med 362(4): 329-344. 16. Sperling, R. A., P. S. Aisen, et al. (2011). "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & dementia: the journal of the Alzheimer's Association 7(3): 280-292. 17. Storandt, M., D. Head, et al. (2012). Toward a multifactorial model of Alzheimer disease. Neurobiol Aging Epub ahead of print (Jan 17). 18. Vellas, B., P.S. Aisen, et al. (2011). Prevention trials in Alzheimer s disease: an EU-US task force report. Progress in Neurobiology 95: 594-600. EMA/CHMP/60715/2012 Page 4/5

19. Weiner, M.W., D.P. Veitch, et al. (2011). The Alzheimer s Disease neuroimaging Initiative: a review of papers published since its inception. Alzheimer s & dementia Epub ahead of print (Oct 31). EMA/CHMP/60715/2012 Page 5/5